Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01419496|
Recruitment Status : Completed
First Posted : August 18, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.
PURPOSE: This research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: protein expression analysis Other: flow cytometry Other: laboratory biomarker analysis|
- Investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in paired diagnostic and relapse samples.
- Investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance.
OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML|
|Study Start Date :||September 2011|
|Primary Completion Date :||May 2016|
- Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples
- Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419496
|Principal Investigator:||Michele S. Redell, MD, PhD||Texas Children's Cancer Center|